J. Cleland

New England Journal of Medicine · 2002–2019

A researcher in the Science corpus: 12 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Who trusts J. Cleland overall

1. Xiaobo Mao
2. N. K. Lakdawala
3. F. McAlister
4. Gui-wen Yi
5. M. Gheorghiade
6. Jeffery Winterfield

Papers from J. Cleland's perspective

Ordered by how strongly the researchers J. Cleland trusts endorse each paper. Same corpus, a different order for every researcher.

1. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. (The Lancet)
2. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. (New England Journal of Medicine)
3. The effect of cardiac resynchronization on morbidity and mortality in heart failure. (New England Journal of Medicine)
4. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. (New England Journal of Medicine)
5. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. (New England Journal of Medicine)
6. PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION
7. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. (The Lancet)
8. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. (The Lancet)
9. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. (The Lancet)
10. Natural History of Asymptomatic Left Ventricular Systolic Dysfunction in the Community (Circulation)

Their papers

• Mitochondrial function as a therapeutic target in heart failure (2016) — 649 citations
• Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations (2019) — 671 citations
• 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). (2013) — 2,183 citations
• State of the art: Using natriuretic peptide levels in clinical practice (2008) — 855 citations
• Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. (2007) — 603 citations
• Rosuvastatin in older patients with systolic heart failure. (2007) — 788 citations
• Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. (2006) — 673 citations
• Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. (2005) — 5,773 citations
• Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: the Trans-European Network-Home-Care Management System (TEN-HMS) study. (2005) — 737 citations
• The effect of cardiac resynchronization on morbidity and mortality in heart failure. (2005) — 6,316 citations
• Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH (2002) — 140 citations
• Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. (2002) — 1,125 citations